ArticleJournal of virology2011
Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms.
Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Independent proviral and antiviral host factors recognize the same capsid protein in divergent human herpesviruses.PLoS pathogens · 2026Article
- Review
- Article
- Review
- Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1.Viruses · 2020Article
- The role of TRIM family proteins in the regulation of cancer stem cell self-renewal.Stem cells (Dayton, Ohio) · 2020Review
- Type-I-IFN-Stimulated Gene TRIM5γ Inhibits HBV Replication by Promoting HBx Degradation.Cell reports · 2019Article
- Restriction of HIV-1 and other retroviruses by TRIM5.Nature reviews. Microbiology · 2019Review
- Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.Clinical and experimental immunology · 2019Review
- Editing of the human TRIM5 gene to introduce mutations with the potential to inhibit HIV-1.PloS one · 2018Article
- Dynamic Modulation of Expression of Lentiviral Restriction Factors in Primary CD4Journal of virology · 2017Article
- TRIMming p53's anticancer activity.Oncogene · 2016Review
- The role of human dendritic cells in HIV-1 infection.The Journal of investigative dermatology · 2015Review
- Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo.Current eye research · 2014Review
- Stabilized human TRIM5α protects human T cells from HIV-1 infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity.Journal of molecular biology · 2014Review
- Dendritic cells in progression and pathology of HIV infection.Trends in immunology · 2014Review
- Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.Journal of virology · 2013Article
- The TRIMCyp genotype in four species of macaques in China.Immunogenetics · 2013Article
- Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TRIM5α is a restriction factor that can block an early step in the retroviral life cycle by recognizing and causing the disassembly of incoming viral capsids, thereby preventing the completion of reverse transcription. Numerous other isoforms of human TRIM5 exist, and isoforms lacking a C-terminal SPRY domain can inhibit the activity of TRIM5α. Thus, TRIM5α activity in a given cell type could be dependent on the relative proportions of TRIM5 isoforms expressed, but little information concerning the relative expression of TRIM5 isoforms in human cells is available. In this study, we demonstrate that mRNAs coding for TRIM5α represent only 50% of total TRIM5 transcripts in human cell lines, CD4(+) T cells, and macrophages. Transcripts coding for, in order of abundance, TRIM5ι (TRIM5-iota), a previously uncharacterized isoform, TRIM5γ, TRIM5δ, and TRIM5κ are also present. Like TRIM5γ and TRIM5δ, TRIM5ι and TRIM5κ do not inhibit HIV-1 replication, but both have dominant-negative activity against TRIM5α. Specific knockdown of TRIM5ι increases TRIM5α activity in human U373-X4 cells, indicating that physiological levels of expression of truncated TRIM5 isoforms in human cells can reduce the activity of TRIM5α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.